Robert John Dempsey

CIK: 0002125298

Transaction Breakdown

Open Market Buys (P)1 (50.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)1 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

OKYO

OKYO Pharma Ltd

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (2 total)

OKYO
OKYO Pharma Ltd
Jul 22, 2026
Purchase(P)
Direct
15K shares at avg. $1.54$23K
OKYO
OKYO Pharma Ltd
Jul 22, 2026
Award(A)
Direct
15K shares at avg. $1.54$23K

		Type	Shares	Price		Ownership
Jul 22, 2026	OKYO OKYO Pharma Ltd	Purchase(P)	15,000	$1.54	$23,085	Direct
Jul 22, 2026	OKYO OKYO Pharma Ltd	Award(A)	15,000	$1.54	$23,085	Direct

1-2 of 2 transactions

About Dempsey Robert John

Dempsey Robert John (SEC CIK 0002125298) files insider reports with the SEC as CHIEF EXECUTIVE OFFICER of OKYO Pharma Ltd (OKYO).

Signal8 holds 3 ownership filings by Dempsey Robert John (1 Form 3, 2 Form 4), filed between May 22, 2026 and Aug 7, 2026. Those filings report 2 transactions, the latest on Jul 22, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Dempsey Robert John's filings is in LONDON.

Recent filings by Dempsey Robert John

Jul 22, 2026: Open-market purchase of OKYO shares (Form 4, code P).
Jul 22, 2026: Grant or award of OKYO shares (Form 4, code A).

Other insiders filing for OKYO Pharma Ltd (OKYO)

BRANCACCIO JOHN P, Director
JACOB GARY S, CHIEF DEVELOPMENT OFFICER
CERRONE GABRIELE M, Director
Mantelli Flavio, CHIEF MEDICAL OFFICER
Patil Rajkumar V., Chief Scientific Officer
Denoyer Bernard, Director

How to read Form 4 transaction codes